PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
7.31%
Cash & equivalents growing 7.31% while Medical - Pharmaceuticals shows decline of -3.31%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
7.31%
Below half the Medical - Pharmaceuticals median of -2.98% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
-2.94%
Inventory growth less than half of Medical - Pharmaceuticals median of 2.32%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
49.07%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
2.55%
Below half the Medical - Pharmaceuticals median of -0.09%. Jim Chanos would question if the company faces working capital strain.
2.43%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.55%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-2.93%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-2.93%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
39.70%
Above 1.5x Medical - Pharmaceuticals median of 1.07%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.74%
1.25-1.5x Medical - Pharmaceuticals median of 1.26%. Mohnish Pabrai notes above-average expansions in non-current assets.
No Data
No Data available this quarter, please select a different quarter.
2.12%
≥ 1.5x the Medical - Pharmaceuticals median of 0.59%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
5.66%
Payables growth below half of Medical - Pharmaceuticals median of -1.28%. Joel Greenblatt sees more conservative payables management vs. peers.
-11.53%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-48.07%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-62.86%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
165.71%
Below half Medical - Pharmaceuticals median of -0.43%. Joel Greenblatt sees fewer expansions than peers.
0.01%
Below half Medical - Pharmaceuticals median of -0.13%. Joel Greenblatt sees more conservative short-term leverage than peers.
-27.28%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
72.86%
Above 1.5x Medical - Pharmaceuticals median of 0.69%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-8.86%
Above 1.5x Medical - Pharmaceuticals median of -0.38%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-0.67%
50-75% of Medical - Pharmaceuticals median of -0.94%. Mohnish Pabrai notes a relatively conservative approach to liabilities.
No Data
No Data available this quarter, please select a different quarter.
9.10%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.96%
≥ 1.5x Medical - Pharmaceuticals median of 0.81%. Joel Greenblatt sees stronger equity growth vs. peers.
2.12%
≥ 1.5x Medical - Pharmaceuticals median of 0.59%. Joel Greenblatt sees more aggressive expansions than peers.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-54.14%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-30.55%
Above 1.5x Medical - Pharmaceuticals median -0.85%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.